|
Antihemophilic factor is a concentrate containing factors VIII and IX — clotting factors that
are used for treatment of persons with hemophilia. Hemophilia is a genetic disorder characterized
by the deficiency or absence of one of the proteins (or factors) in blood plasma that is responsible
for clotting. Low levels of one of these plasma proteins result in bleeding and difficulty clotting
in the affected individual. The most common deficiencies of clotting proteins are factor VIII and
factor IX. A doctor or healthcare provider prescribes antihemophilic therapies.
Please note: Country-specific regulatory requirements limit the information we can provide about our products. In addition,
approved indications (uses), product labels, and packaging for a prescription drug may differ between
countries. Please refer to the prescribing information provided for your country of residence.
Koate®-DVI (Antihemophilic Factor [Human]) reaches patients around the world, including in:
Antithrombin III (AT-III) is a blood protein that inhibits or stops the clotting factors
in blood. Approximately 75% of the body's plasma coagulation inhibitory activity is derived
from AT-III. AT-III deficiency is a rare inherited or spontaneously occurring condition
that affects one in every 2,000 to 5,000 males and females worldwide. Individuals with
the condition lack the AT-III protein and spontaneous clotting can occur as a result of
normal, daily activity. A doctor or healthcare provider prescribes Antithrombin III.
Please note: Country-specific regulatory requirements limit the information we can provide about our products. In addition,
approved indications (uses), product labels, and packaging for a prescription drug may differ between
countries. Please refer to the prescribing information provided for your country of residence.
Thrombate III®, Antithrombin III (Human) reaches patients around the world, including in:
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|